**vartis bid to
sell new
biosimilar crimped by
U.S. court battles
ZURICH (Reuters) -
**vartis has won
U.S. approval for a copy of Amgen's blockbuster arthritis drug Enbrel, but the Swiss drugmaker's bid to muscle in on the medicine's $4.7 billion in annual
U.S. revenue remains blocked by
court battles.
